| Literature DB >> 24741621 |
Katarzyna Kotarska1, Ewa Wunsch2, Agnieszka Kempińska-Podhorodecka3, Joanna Raszeja-Wyszomirska4, Dimitrios P Bogdanos5, Maciej Wójcicki6, Piotr Milkiewicz4.
Abstract
BACKGROUND/AIM: With the improvement of the outcomes after liver transplantation (LTx), health-related quality of life (HRQoL) and physical activity are becoming significant outcome parameters. We prospectively assessed these parameters in patients with autoimmune and nonautoimmune liver disorders undergoing LTx.Entities:
Mesh:
Year: 2014 PMID: 24741621 PMCID: PMC3987938 DOI: 10.1155/2014/738297
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Demographic and clinical data on analyzed patients.
| Total number of patients |
|
| Age at transplantation [years, mean ± SD (range)] | 46.7 ± 11.6 (17–63) |
| Age at survey [years, mean ± SD (range)] | 49.9 ± 11.4 (21–67) |
| Gender [male/female] | 62 (57.9%)/45 (42.1%) |
| BMI [kg/m2, mean ± SD (range)] | 27.0 ± 5.0 (18.0–43.0) |
| Period after transplantation | |
| Group-A (6–12 months) | 21 (19.6%) |
| Group-B (13–36 months) | 48 (44.9%) |
| Group-C ( >36 months) | 38 (35.5%) |
| Employment (yes/no) | 40 (37.4%)/67 (62.6%) |
| Original diagnosis | |
| Alcohol liver disease | 24 (22.4%) |
| Viral hepatitides | 15 (14.0%) |
| Autoimmune hepatitis | 10 (9.4%) |
| Autoimmune cholestatic (PBC, PSC) | 23 (21.5%) |
| Other* | 35 (32.7%) |
Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation; *other reasons for LTx included cryptogenic cirrhosis (n = 8); Fulminant Wilson's (n = 5), chronic Wilson's (n = 2); non-A, non-B hepatitis (n = 7); amanita poisoning (n = 7); Budd-Chiari syndrome (n = 4); secondary biliary cirrhosis (n = 1) and acute fatty liver of pregnancy (n = 1). BMI: body mass index; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis.
Quality of life and physical activity after liver transplantation in patients with autoimmune versus nonautoimmune etiology of liver disease.
| Autoimmune ( | Nonautoimmune ( |
| |
|---|---|---|---|
| SF 36 | |||
| PF | 69.1 ± 23.4 | 73.8 ± 23.3 | 0.339 |
| RP | 62.1 ± 23.3 | 64.6 ± 24.6 | 0.624 |
| BP | 66.5 ± 27.7 | 73.6 ± 28.1 | 0.232 |
| GH | 56.8 ± 21.4 | 60.8 ± 18.7 | 0.335 |
| VT | 60.4 ± 16.9 | 61.4 ± 18.0 | 0.790 |
| SF | 72.0 ± 19.0 | 74.7 ± 24.1 | 0.572 |
| RE | 72.2 ± 21.8 | 75.7 ± 22.2 | 0.457 |
| MH | 66.2 ± 17.8 | 67.8 ± 16.4 | 0.650 |
| PCS | 44.9 ± 8.9 | 47.0 ± 8.7 | 0.256 |
| MCS | 46.0 ± 8.6 | 47.7 ± 9.8 | 0.732 |
|
| |||
| IPAQ | |||
| Total (MET-min/week) | 4464.4 ± 3370.3 | 4511.7 ± 3401.0 | 0.947 |
| Walking (MET-min/week) | 1483.0 ± 901.6 | 1198.7 ± 907.2 | 0.137 |
| Moderate (MET-min/week) | 2077.1 ± 1043.8 | 2548.2 ± 1474.1 | 0.100 |
| Vigorous (MET-min/week) | 904.2 ± 3147.2 | 764.9 ± 3174.2 | 0.834 |
| Sitting time (min/week) | 620.0 ± 182.9 | 639.5 ± 181.5 | 0.610 |
All values are shown as mean ± SD.
PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PF: physical functioning; PCS: physical component score; MCS: mental component score.
(a)
| SF 36 | Males ( | Females ( |
|
|---|---|---|---|
| PF | 78.5 ± 22.2 | 63.9 ± 22.5 | 0.001 |
| RP | 67.6 ± 26.2 | 58.6 ± 20.0 | 0.05 |
| BP | 79.4 ± 25.4 | 60.5 ± 28.2 | 0.0004 |
| GH | 61.9 ± 20.2 | 56.3 ± 18.4 | 0.14 |
| VT | 64.9 ± 16.1 | 55.8 ± 18.4 | 0.0077 |
| SF | 79.4 ± 20.4 | 66.1 ± 79.4 | 0.0023 |
| RE | 81.5 ± 20.0 | 65.2 ± 21.5 | 0.0001 |
| MH | 71.1 ± 15.4 | 62.1 ± 17.4 | 0.0057 |
| PCS | 48.2 ± 9.1 | 43.7 ± 7.6 | 0.0073 |
| MCS | 48.9 ± 8.2 | 43.1 ± 9.9 | 0.0015 |
(b)
| SF 36 | A
( | B
( | C
( |
|
|
|
|---|---|---|---|---|---|---|
| PF | 66.7 ± 25.1 | 71.8 ± 25.7 | 76.2 ± 18.7 | 0.405 | 0.136 | 0.386 |
| RP | 55.4 ± 24.9 | 65.6 ± 23.0 | 66.3 ± 24.8 | 0.105 | 0.096 | 0.899 |
| BP | 62.2 ± 25.2 | 74.2 ± 27.7 | 73.0 ± 29.6 | 0.105 | 0.159 | 0.845 |
| GH | 52.7 ± 18.5 | 63.4 ± 18.5 | 58.4 ± 20.7 |
| 0.280 | 0.239 |
| VT | 61.0 ± 15.3 | 60.6 ± 17.9 | 61.8 ± 18.8 | 0.920 | 0.864 | 0.737 |
| SF | 75.6 ± 21.1 | 77.1 ± 23.7 | 68.8 ± 21.7 | 0.801 | 0.266 | 0.091 |
| RE | 68.7 ± 25.4 | 75.2 ± 22.2 | 77.2 ± 19.8 | 0.261 | 0.157 | 0.674 |
| MH | 67.9 ± 11.7 | 67.0 ± 17.3 | 67.5 ± 18.8 | 0.839 | 0.938 | 0.882 |
| PCS | 42.5 ± 8.8 | 47.3 ± 8.4 | 47.2 ± 8.9 |
| 0.051 | 0.967 |
| MCS | 47.0 ± 8.6 | 46.6 ± 9.6 | 46.9 ± 9.8 | 0.8819 | 0.6964 | 0.7569 |
All values are shown as mean ± SD.
Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation.
PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PF: physical functioning; PCS: physical component score; MCS: mental component score.
(a)
| SF 36 | Employed
( | Pensioners
( |
|
|---|---|---|---|
| PF |
|
|
|
| RP |
|
|
|
| BP |
|
|
|
| GH | 61.6 ± 23.4 | 58.3 ± 16.9 | 0.407 |
| VT | 63.5 ± 17.1 | 59.7 ± 17.8 | 0.298 |
| SF | 77.8 ± 22.4 | 71.5 ± 22.6 | 0.161 |
| RE |
|
|
|
| MH | 71.0 ± 17.3 | 65.2 ± 16.2 | 0.083 |
| PCS |
|
|
|
| MCS | 48.3 ± 8.6 | 45.4 ± 9.7 | 0.113 |
(b)
| SF 36 | 1
( | 2
( | 3
( |
|
|
|
|---|---|---|---|---|---|---|
| PF |
|
|
| 0.59 |
|
|
| RP | 65.1 ± 24.5 | 66.8 ± 24.1 | 56.5 ± 22.96 | 0.75 | 0.17 | 0.11 |
| BP | 71.9 ± 27.9 | 74.3 ± 29.03 | 65.6 ± 26.9 | 0.69 | 0.38 | 0.25 |
| GH | 60.4 ± 19.7 |
|
| 0.46 | 0.07 |
|
| VT | 60.9 ± 20.2 | 63.5 ± 15.5 | 57.6 ± 15.2 | 0.49 | 0.47 | 0.21 |
| SF | 71.2 ± 24.3 | 75.98 ± 21.8 | 75.5 ± 20.8 | 0.34 | 0.45 | 0.94 |
| RE | 73.4 ± 24.6 | 76.1 ± 19.8 | 74.6 ± 21.1 | 0.58 | 0.82 | 0.80 |
| MH | 66.2 ± 16.7 | 70.2 ± 18.1 | 64.8 ± 14.7 | 0.28 | 0.74 | 0.22 |
| PCS |
|
|
| 0.71 |
|
|
| MCS | 45.2 ± 10.6 | 47.3 ± 8.6 | 47.5 ± 8.04 | 0.32 | 0.36 | 0.95 |
All values are shown as mean ± SD.
Group 1: normal BMI (18–25 kg/m2), group 2: overweight (BMI 25–30 kg/m2), group 3: obese (BMI 25–30 kg/m2).
PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: mental health; PF: physical functioning; PCS: physical component score; MCS: mental component score.
(a)
| IPAQ | Males
( | Females
( |
|
|---|---|---|---|
| Total (MET-min/week) | 4912.8 ± 4027.8 | 3924.4 ± 2093.3 | 0.136 |
| Walking (MET-min/week) | 1222.9 ± 794.8 | 1373.9 ± 1053.3 | 0.399 |
| Moderate (MET-min/week) | 2342.2 ± 1322.9 | 2486.5 ± 1440.2 | 0.593 |
| Vigorous (MET-min/week) |
|
|
|
| Sitting time (min-week) | 621.9 ± 176.1 | 649.3 ± 189.0 | 0.443 |
(b)
| IPAQ | A (n = 21) | B
( | C
( |
|
|
|
|---|---|---|---|---|---|---|
| Total (MET-min/week) | 3697.6 ± 2053.3 | 5333.4 ± 4553.7 | 3882.6 ± 1538.9 | 0.06 | 0.83 |
|
| Walking (MET-min/week) | 1216.2 ± 890.5 | 1350.6 ± 1027.7 | 1244 ± 772.4 | 0.577 | 0.912 | 0.594 |
| Moderate (MET-min/week) | 2119.5 ± 1158.7 | 2548.7 ± 1601.4 | 2375.4 ± 1144.3 | 0.235 | 0.494 | 0.562 |
| Vigorous (MET-min/week) | 361.9 ± 1568.0 | 1464.2 ± 4506.9 | 263.2 ± 632.6 | 0.193 | 0.91 | 0.08 |
| Sitting time (min-week) | 720.0 ± 171.8 | 605.8 ± 174.5 | 620.5 ± 184.7 |
|
| 0.7 |
All values are shown as mean ± SD.
Group-A: 6 months to 12 months after liver transplantation; group-B: from 12 months to 36 months after liver transplantation; group-C: over 36 months after liver transplantation.
(a)
| IPAQ | Employed
( | Pensioners
( |
|
|---|---|---|---|
| Total (MET-min/week) | 5668.2 ± 4787.0 | 3797.9 ± 1852.8 |
|
| Walking (MET-min/week) | 1287.5 ± 870.9 | 1287.5 ± 985.5 | 0.98 |
| Moderate (MET-min/week) | 2340.7 ± 1451.7 | 2440.0 ± 1326.5 | 0.71 |
| Vigorous (MET-min/week) | 2043.0 ± 4934.6 | 70.5 ± 296.9 |
|
| Sitting time (min-week) | 632.5 ± 173.2 | 634.0 ± 187.2 | 0.96 |
(b)
| IPAQ | 1
( | 2
( | 3
( |
|
|
|
|---|---|---|---|---|---|---|
| Total (MET-min/week) |
|
|
|
|
| 0.93 |
| Walking (MET-min/week) | 1361.2 ± 1179.2 | 1283.1 ± 686.8 | 1142.1 ± 571.1 | 0.70 | 0.35 | 0.56 |
| Moderate (MET-min/week) | 2600.5 ± 1294.0 | 2109.8 ± 1337.5 | 2491.7 ± 1534.2 | 0.10 | 0.75 | 0.29 |
| Vigorous (MET-min/week) |
|
| 83.5 ± 400.3 |
| 0.054 | 0.83 |
| Sitting time (min-week) | 663.5 ± 182.9 | 593.7 ± 183.9 | 639.1 ± 168.4 | 0.08 | 0.59 | 0.34 |
All values are shown as mean ± SD.
Group 1: normal BMI (18–25 kg/m2); group 2: overweight (BMI 25–30 kg/m2); group 3: obese (BMI 25–30 kg/m2).